Keyphrases
Advanced Hepatocellular Carcinoma
17%
Adverse Events
8%
Albumin-bilirubin Grade
14%
Alpha-fetoprotein
5%
Antigen-specific Antibody
5%
Array chip
6%
Atezolizumab
5%
Atezolizumab Plus Bevacizumab
33%
Bevacizumab
6%
Bevacizumab Treatment
7%
Child-Pugh Score
5%
Clinical Features
5%
Confidence Interval
16%
Drug-induced Liver Injury
5%
Hazard Ratio
16%
Hepatic Function
9%
Hepatitis B Surface Antigen (HBsAg)
7%
Hepatitis B Virus
8%
Hepatitis B Virus Infection
6%
Hepatocellular Carcinoma
37%
Hepatocellular Carcinoma Patients
24%
Inverse Probability Weighting
6%
Japan
7%
Lenvatinib
52%
Liver
10%
Liver Disease
11%
Lymphocytes
5%
Microwell Array
6%
Monoclonal Antibody
8%
Multivariate Analysis
7%
Nonalcoholic Steatohepatitis
6%
Overall Survival
17%
Progression-free Survival
12%
Sorafenib
14%
Therapeutic Efficacy
5%
Tumor
7%
Unresectable Hepatocellular Carcinoma
46%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
11%
Atezolizumab
40%
Bevacizumab
39%
Bilirubin
15%
Chemotherapy
5%
Combination Therapy
8%
Disease
10%
Hepatitis B
5%
Hepatitis B Virus
7%
Lenvatinib
50%
Liver Cancer
5%
Liver Cell Carcinoma
100%
Liver Cirrhosis
6%
Liver Disease
9%
Liver Injury
6%
Neoplasm
6%
Nonalcoholic Fatty Liver
6%
Overall Survival
27%
Progression Free Survival
17%
Sorafenib
14%
Toxic Hepatitis
5%
Medicine and Dentistry
Adverse Event
8%
Atezolizumab
24%
Bevacizumab
23%
Bilirubin
11%
Chemotherapy
5%
Disease
7%
Hazard Ratio
12%
Hepatitis B Virus
7%
Hepatocellular Carcinoma
85%
Lenvatinib
46%
Liver Cirrhosis
7%
Liver Disease
9%
Liver Function
12%
Lymphocyte
12%
Multivariate Analysis
5%
Neoplasm
12%
Neutrophil
6%
Nonalcoholic Fatty Liver
7%
Overall Survival
17%
Prognostic Factor
5%
Progression Free Survival
11%
Radiofrequency Ablation
5%
Sorafenib
7%